APA (7th ed.) Citation

Jinhong Gong, Jinhong Gong, Dan Su, Jingjing Shang, Shan Xu, Lidan Tang, . . . Guangjun Liu. (2022). Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Jinhong Gong, Jinhong Gong, Dan Su, Jingjing Shang, Shan Xu, Lidan Tang, Zhiqiang Sun, and Guangjun Liu. Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. Frontiers Media S.A., 2022.

MLA (9th ed.) Citation

Jinhong Gong, et al. Cost-Effectiveness of Tislelizumab Versus Docetaxel for Previously Treated Advanced Non-Small-Cell Lung Cancer in China. Frontiers Media S.A., 2022.